Mark Bodmer and Jonathan Lewis of UCB pharma talk us though the partnering model at UCB, and how partnering can drive innovation. The world is changing and it’s no different for the ...

Barclays analyst Charles Pitman CFA reiterated a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €240.00. The company’s shares closed last Friday at €179.89.

The 2025 guidelines also emphasize transparency, data quality, and continuous monitoring. From February 2, 2025, pharmaceutical companies in the European Union (EU) region must comply with AI ...

Pharmaceutical companies control and hide ... can take immediate action as part of his prioritization of “radical transparency” to aid his mission to “Make America Healthy Again.” ...

Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $180.00. The company’s shares closed last Friday at ...

UCB and Sanofi have unveiled a scientific and strategic collaboration to discover and develop novel treatments for immune-mediated diseases in areas such as gastroenterology and arthritis.

Indian pharma is focusing on strengthening post-marketing surveillance (PMS) and improving supply chain transparency for over-the-counter (OTC) drugs. This is in a bid to ensure patient safety, ...

All dollar values are in U.S. dollars unless stated otherwise. Eupraxia Pharmaceuticals logo (CNW Group/Eupraxia Pharmaceuticals Inc.) On October 2, 2024, the Company announced the appointment of ...

While such apps promise increased security and privacy, they often skirt open records laws meant to increase transparency around and public awareness of government decision-making. Without special ...